Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04933669

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01)

Sponsor: First Affiliated Hospital of Wenzhou Medical University

Conditions Gastrointestinal Stromal Tumor Neoadjuvant Progression-free Survival

Interventions Imatinib

Updated 5 times since 2021 Last updated: Oct 9, 2021 Started: Sep 7, 2021 Primary completion: Dec 31, 2029 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastrointestinal Stromal Tumor and Neoadjuvant, this trial is actively recruiting participants. The trial is conducted by First Affiliated Hospital of Wenzhou Medical University and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Nov 2021 — Nov 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
Ningbo No. 1 Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sir Run Run Shaw Hospital
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Zhejiang Cancer Hospital

Data source: First Affiliated Hospital of Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China